Artem Kuzmenko, Partner
Dmytro Maksymov, Associate
The government is speeding up the supply of imported medicines, but Ukraine issued its first parallel import authorisation only in June 2026. What is holding back competition, and how should potential savings be measured?
On 13 October, the government simplified state quality control procedures for imported medicines. During martial law, an authorised representative of the importer may inspect the consignment and document the inspection with photographs. If the same importer brings in a batch again after it has passed inspection and received a favourable quality assessment, the rules provide for a visual check within one working day. This rule applies to medicines manufactured in the countries listed in the government resolution.
Parallel imports, a separate route for supplying medicines from Europe, remain subject to their own authorisation procedure. The main legislative provisions took effect on 1 January 2025, and the procedure for granting authorisations came into force on 15 April 2025. Ukraine’s State Service on Medicines and Drugs Control issued the first authorisation in June 2026 for imipenem/cilastatin, an antibiotic manufactured by Italy’s ACS Dobfar. As of 6 November, the published list of regulatory orders contained only one decision granting an authorisation.
The law imposes two major restrictions. Each medicine requires a separate authorisation, and pharmacies are prohibited from selling parallel-imported medicines. These rules determine the cost of entering the market and which buyers importers can reach. Together, they shape whether supplying medicines to Ukraine makes commercial sense.
The first barrier is a separate authorisation for each medicine
To obtain authorisation, an importer must demonstrate that the medicine meets the criteria set out in Article 78 of the law. When assessing whether medicines are identical or similar, the regulator compares their active substances, pharmaceutical form, strength, indications and route of administration. A matching name on the packaging is insufficient. The regulator has 45 calendar days to decide and may stop the clock while awaiting clarification. The applicant pays for the State Expert Centre’s review of the dossier under a contract.
The first decisions illustrate the issues that arise during assessment. In November 2025, the regulator refused two applications for meropenem because the documentation was incomplete, the proposed arrangements for placing the medicine on the market had not been agreed, and the representative’s authority had not been verified. In May 2026, the regulator also refused two resubmitted applications covering the same strengths. It found that the applicant had failed to demonstrate that the difference in shelf life would have no impact on safety, quality or efficacy. The packaging, diluents and indications also differed.
The second barrier is the ban on pharmacy sales
Even with an authorisation, sales are far from assured. The law permits wholesale distribution of parallel-imported medicines, including supplies to hospitals and the authorised procurement body. It expressly prohibits their sale and dispensing through pharmacies.
An import is commercially viable if the purchase price, together with authorisation costs, logistics and taxes, allows the importer to compete with existing suppliers. The question is where those opportunities exist.
How much could parallel imports save?
To estimate savings for Ukrainian hospitals, buyers need to compare final offers for the same medicines at comparable volumes, delivery times, remaining shelf lives and payment terms. Retail pharmacy prices are of limited use. They tell buyers little about the price at which a European supplier would sell a batch for Ukraine or the volume it could supply. Experience in other countries illustrates the potential of parallel imports. Estimating savings in Ukraine still requires a comparison of actual offers.
In a price comparison published by Apteka in December 2024, Ukrainian prices were lower than those in the EU countries studied for 85% of the selected products outside state reimbursement schemes. Across a sample of 73 product lines, the weighted average price per pack was 30% lower in Ukraine. The findings are specific to that sample and period. They offer no basis for drawing conclusions about the market as a whole or forecasting savings from parallel imports.
Denmark illustrates what parallel imports could achieve. There, parallel-imported medicines are sold to both pharmacies and hospitals. Copenhagen Economics estimated savings of DKK 665 million in 2025, equivalent to around 2% of total spending on medicines. The hospital sector accounted for DKK 82 million of those savings. The study estimated that parallel-imported medicines were, on average, 22% cheaper in the pharmacy sector and 12% cheaper in the hospital sector than they would have been in the absence of parallel imports. These percentages apply only to the medicines imported through this route. The study attributed DKK 40 million of the hospital savings to the indirect effects of competition.
There are limits to what can be inferred from these estimates. An association of parallel importers commissioned the study. Manufacturers’ actual bids in hospital tenders were confidential, so the authors modelled their prices and acknowledged considerable uncertainty in the hospital estimate.
It is therefore too early to promise widespread price reductions from parallel imports alone. Their potential should be tested medicine by medicine, including for high-cost originator products where a more competitive supply offer is available. An additional bidder may also prompt the incumbent supplier to lower its price. For that to happen, importers must have a commercial reason to enter the Ukrainian market. Secondary legislation could address some procedural issues, while opening the pharmacy channel would require an amendment to the law.
What should change in the law and the procedure?
The authorisation should remain in place because it confirms that the medicine meets the criteria for parallel import. The question is whether the costs of preparing and reviewing dossiers could be reduced while maintaining those criteria.
First, the current procedure already allows pack sizes to be changed by amending the dossier. A next step would be to allow a joint submission and issue a single authorisation covering specified strengths and pack sizes of the same medicine. Each variant would still have to meet the requirements individually, while documents common to several variants could be reviewed together.
Second, for medicines made by the same manufacturer at the same production site, the regulator should consider reducing duplicate checks where existing evidence already establishes compliance with all parallel import criteria. A shared manufacturer is only one part of the assessment. Composition, strength, indications, shelf life and packaging must also be verified.
Third, alongside publishing regulatory orders and giving reasons for decisions, as the rules already require, the regulator should publish aggregate data on how long each stage of assessment takes in practice and why applications are refused. This would help distinguish the time spent by the regulator and the State Expert Centre from the time applicants spend responding to requests for clarification. That evidence would help determine which procedures need to change.
Simplifying authorisation would leave the statutory ban on pharmacy sales in place. The next step would be to open the pharmacy channel gradually, while maintaining quality controls, batch traceability and pharmacovigilance. It would also be necessary to assess whether the current requirements for packaging and Ukrainian-language information are sufficient for dispensing to patients.
How a lower-priced offer affects purchasing decisions also matters. In Denmark, a pharmacy must offer the lowest-priced pack in a designated group of interchangeable medicines unless the prescriber has prohibited substitution. This is one of the mechanisms that support price competition.
Ukraine’s Affordable Medicines programme already allows a choice between brands of medicines with the same international non-proprietary name. The programme is one possible setting for a pilot. This would require specific rules for adding parallel-imported medicines to the programme’s lists and enabling authorisation holders to participate in the state reimbursement scheme. Any decision to expand the pilot should depend on verified savings, compliance with quality requirements and whether suppliers have met their delivery commitments.
Giving parallel importers access to more buyers would affect manufacturers and their authorised distributors. An exclusive contract between a manufacturer and a distributor imposes no contractual obligations on a parallel importer who is outside that agreement. The importer must still comply with repackaging and labelling requirements and take account of trade mark rules, patent rights and the applicable statutory exceptions.
How to measure success
The first authorisation showed that the procedure works. Whether parallel imports develop into a viable supply channel will depend on the cost of obtaining authorisation and supplying medicines, as well as on who is allowed to buy them. The government should judge success by contracts fulfilled, competition in procurement and verified savings for the healthcare system.